1. Seddon, B, Strauss, SJ, Whelan, J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1397–1410.
Google Scholar | Crossref | Medline2. Maki, RG, Wathen, JK, Patel, SR, et al. Randomized phase II study of gemcitabine and docetaxel compared With gemcitabine alone in patients With metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25: 2755–2763.
Google Scholar | Crossref | Medline | ISI3. Demetri, GD, Von Mehren, M, Jones, RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016; 34: 786.
Google Scholar | Crossref | Medline | ISI4. Van Der Graaf, WT, Blay, J-Y, Chawla, SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879–1886.
Google Scholar | Crossref | Medline | ISI5. Schöffski, P, Chawla, S, Maki, RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387: 1629–1637.
Google Scholar | Crossref | Medline | ISI6. Jones, RL, Mo, G, Baldwin, JR, et al. Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. Cancer Chemother Pharmacol 2019; 83: 191–199.
Google Scholar | Crossref | Medline7. Pietras, K, Rubin, K, Sjöblom, T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62: 5476–5484.
Google Scholar | Medline | ISI8. Chiorean, EG, Sweeney, C, Youssoufian, H, et al. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73: 595–604.
Google Scholar | Crossref | Medline | ISI9. Doi, T, Ma, Y, Dontabhaktuni, A, et al. Phase I study of olaratumab in Japanese patients with advanced solid tumors. Cancer Sci 2014; 105: 862–869.
Google Scholar | Crossref | Medline | ISI10. Tap, WD, Jones, RL, Van Tine, BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016; 388: 488–497.
Google Scholar | Crossref | Medline | ISI11. Penniman, L, Parmar, S, Patel, K. Olaratumab (Lartruvo): an innovative treatment for soft tissue sarcoma. PT 2018; 43: 267.
Google Scholar | Medline12. Shirley, M. Olaratumab: first global approval. Drugs 2017; 77: 107–112.
Google Scholar | Crossref | Medline13. Tap, WD, Wagner, AJ, Schöffski, P, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. JAMA 2020; 323: 1266–1276.
Google Scholar | Crossref | Medline14. Eli Lilly Company . Lilly to establish an access program for patients as it prepares to withdraw Lartruvo from the global market. Eli Lilly Company, 2019.
Google Scholar15. Beaver, JA, Howie, LJ, Pelosof, L, et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol 2018; 4: 849–856.
Google Scholar | Crossref | Medline16. Striefler, JK, Brandes, F, Baur, A, et al. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma-a single-Centre experience. BMC Cancer 2020; 20: 68.
Google Scholar | Crossref | Medline17. Seeber, A, Weiss, L, Romeder, F, et al. Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma. Wien Klin Wochenschr 2021; 133: 21–25.
Google Scholar | Crossref | Medline18. Gennatas, S, Chamberlain, F, Carter, T, et al. Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. Clin Sarcoma Res 2020; 10: 1–7.
Google Scholar | Crossref | Medline19. Vornicova, O, Haim, N, Bar-Sela, G. A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma. Cancer Chemother Pharmacol 2019; 84: 919–923.
Google Scholar | Crossref | Medline20. Hammer, KJ, Copeland, VC, Loggers, ET, et al. Doxorubicin and olaratumab versus doxorubicin, ifosfamide, and mesna for treatment of advanced soft tissue sarcomas. Am J Clin Oncol 2020; 43: 446–451.
Google Scholar | Crossref | Medline21. Tobias, A, O’brien, MP, Agulnik, M. Olaratumab for advanced soft tissue sarcoma. Expert Rev Clin Pharmacol 2017; 10: 699–705.
Google Scholar | Crossref | Medline22. Ogihara, Y, Takeda, K, Yanagawa, T, et al. Spontaneous regression of lung metastases from osteosarcoma. Cancer 1994; 74: 2798–2803.
Google Scholar | Crossref | Medline23. Shen, JK, Cote, GM, Choy, E, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2014; 2: 690–698.
Google Scholar | Crossref | Medline24. Tsukahara, T, Emori, M, Murata, K, et al. The future of immunotherapy for sarcoma. Expert Opin Biol Ther 2016; 16: 1049–1057.
Google Scholar | Crossref | Medline25. Tsukahara, T, Kawaguchi, S, Torigoe, T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006; 97: 1374–1380.
Google Scholar | Crossref | Medline26. Hatina, J, Kripnerova, M, Houfkova, K, et al. Sarcoma stem cell heterogeneity. Adv Exp Med Biol 2019; 1123: 95–118.
Google Scholar | Crossref | Medline